{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T06:28:02Z","timestamp":1788589682735,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"The Innovation & Value Initiative"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s40273-019-00827-z","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T05:03:07Z","timestamp":1565154187000},"page":"1313-1320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project"],"prefix":"10.1007","volume":"37","author":[{"given":"Jeroen P.","family":"Jansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Incerti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Linthicum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,7]]},"reference":[{"issue":"9","key":"827_CR1","first-page":"632","volume":"21","author":"LP Garrison","year":"2015","unstructured":"Garrison LP, Carlson JJ, Bajaj PS, Towse A, Neumann PJ, Sullivan SD, et al. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects. Am J Manag Care. 2015;21(9):632\u201340.","journal-title":"Am J Manag Care."},{"issue":"2","key":"827_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jval.2017.12.011","volume":"21","author":"RJ Willke","year":"2018","unstructured":"Willke RJ, Neumann PJ, Garrison LP Jr, Ramsey SD. Review of recent US value frameworks: a health economics approach: an ISPOR Special Task Force Report. Value Health. 2018;21(2):155\u201360.","journal-title":"Value Health."},{"issue":"2","key":"827_CR3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jval.2017.12.006","volume":"21","author":"LP Garrison Jr","year":"2018","unstructured":"Garrison LP Jr, Pauly MV, Willke RJ, Neumann PJ. An overview of value, perspective, and decision context: a health economics approach: an ISPOR Special Task Force Report. Value Health. 2018;21(2):124\u201330.","journal-title":"Value Health."},{"issue":"2","key":"827_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","volume":"21","author":"DN Lakdawalla","year":"2018","unstructured":"Lakdawalla DN, Doshi JA, Garrison LP Jr, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care: a health economics approach. An ISPOR Special Task Force Report. Value Health. 2018;21(2):131\u20139.","journal-title":"Value Health."},{"key":"827_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/1472-6963-8-270","volume":"8","author":"M Goetghebeur","year":"2008","unstructured":"Goetghebeur M, Wagner M, Khoury H, et al. Evidence and value: impact on DEcisionMaking: the EVIDEM framework and potential applications. BMC Health Serv Res. 2008;8:270.","journal-title":"BMC Health Serv Res."},{"key":"827_CR6","unstructured":"Thokala P. Multiple criteria decision analysis for health technology assessment: report by the decision support unit, School of Health and Related Research. Sheffield: University of Sheffield. 2011."},{"issue":"1","key":"827_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1017\/S0266462313000639","volume":"30","author":"G Radaelli","year":"2014","unstructured":"Radaelli G, Lettieri E, Masella C, Merlino L, Strada A, Tringali M. Implementation of EunetHTA core model\u00ae in Lombardia: the VTS framework. Int J Technol Assess Health Care. 2014;30(1):105\u201312.","journal-title":"Int J Technol Assess Health Care."},{"key":"827_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40273-014-0135-0","volume":"32","author":"K Marsh","year":"2014","unstructured":"Marsh K, Lanitis T, Neasham D, Orfanos P, Caro J. Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature. Pharmacoeconomics. 2014;32:345\u201365.","journal-title":"Pharmacoeconomics"},{"key":"827_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40273-018-00765-2","volume":"37","author":"D Incerti","year":"2019","unstructured":"Incerti D, Curtis JR, Shafrin J, Lakdawalla DN, Jansen JP. A flexible open-source decision model for value assessment of biologic treatment for rheumatoid arthritis. Pharmacoeconomics. 2019;37:829\u201343.","journal-title":"Pharmacoeconomics"},{"key":"827_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40273-016-0479-8","volume":"35","author":"WC Dunlop","year":"2017","unstructured":"Dunlop WC, Mason N, Kenworthy J, Akehurst RL. Benefits, challenges and potential strategies of open source health economic models. Pharmacoeconomics. 2017;35:125\u20138.","journal-title":"Pharmacoeconomics"},{"key":"827_CR11","first-page":"115","volume":"226","author":"W Schramm","year":"2016","unstructured":"Schramm W, Sailer F, Pobiruchin M, Weiss C. PROSIT open source disease models for diabetes mellitus. Stud Health Technol Inform. 2016;226:115\u20138.","journal-title":"Stud Health Technol Inform"},{"issue":"7","key":"827_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/L17-0695","volume":"168","author":"JT Cohen","year":"2018","unstructured":"Cohen JT, Neumann PJ, Wong JB. A call for open-source cost-effectiveness analysis. Ann Intern Med. 2018;168(7):529.","journal-title":"Ann Intern Med"},{"key":"827_CR13","unstructured":"Incerti D, Jansen JP. A description of the IVI-NSCLC model v1.0; last updated January 31, 2019. \nhttps:\/\/innovationvalueinitiative.github.io\/IVI-NSCLC\/modeldoc\/model-doc.pdf\n\n. Accessed 26 Jul 2019."},{"key":"827_CR14","unstructured":"Incerti D, Jansen JP. Hesim: an R package for high performance health-economic simulation modeling. R package version 0.2.1. 2019."},{"key":"827_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jpubeco.2016.11.012","volume":"145","author":"D Lakdawalla","year":"2017","unstructured":"Lakdawalla D, Malani A, Julian R. The insurance value of medical innovation. J Public Econ. 2017;145:94\u2013102.","journal-title":"J Public Econ"},{"key":"827_CR16","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1377\/hlthaff.2011.1300","volume":"31","author":"DN Lakdawalla","year":"2012","unstructured":"Lakdawalla DN, Romley JA, Sanchez Y, et al. How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. Health Aff (Millwood). 2012;31:676\u201382.","journal-title":"Health Aff (Millwood)"},{"issue":"6","key":"827_CR17","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.healthpol.2018.04.008","volume":"122","author":"J Shafrin","year":"2018","unstructured":"Shafrin J, Skornicki M, Brauer M, Villeneuve J, Lees M, Hertel N, et al. An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: does it make a difference? Health Policy. 2018;122(6):607\u201313.","journal-title":"Health Policy."},{"issue":"21","key":"827_CR18","doi-asserted-by":"publisher","first-page":"4340","DOI":"10.1002\/sim.3305","volume":"27","author":"M Fiocco","year":"2008","unstructured":"Fiocco M, Putter H, van Houwelingen HC. Reduced-rank proportional hazards regression and simulation-based prediction for multi-state models. Stat Med. 2008;27(21):4340\u201358.","journal-title":"Stat Med"},{"issue":"7","key":"827_CR19","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1177\/0272989X16686559","volume":"37","author":"H Jalal","year":"2017","unstructured":"Jalal H, Pechlivanoglou P, Krijkamp E, Alarid-Escudero F, Enns E, Hunink MGM. An overview of R in health decision sciences. Med Decis Making. 2017;37(7):735\u201346.","journal-title":"Med Decis Making."},{"key":"827_CR20","doi-asserted-by":"crossref","unstructured":"Baio G, Berardi A, Heath A. BCEA: Bayesian cost effectiveness analysis. R package version 2.2.6. 2018.","DOI":"10.1007\/978-3-319-55718-2"},{"issue":"3","key":"827_CR21","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/0272989X9001000308","volume":"10","author":"WC Black","year":"1990","unstructured":"Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making. 1990;10(3):212\u20134.","journal-title":"Med Decis Making"},{"issue":"8","key":"827_CR22","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/hec.635","volume":"10","author":"E Fenwick","year":"2001","unstructured":"Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10(8):779\u201387.","journal-title":"Health Econ"},{"issue":"5","key":"827_CR23","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/j.1524-4733.2008.00358.x","volume":"11","author":"GR Barton","year":"2008","unstructured":"Barton GR, Briggs AH, Fenwick EA. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health. 2008;11(5):886\u201397.","journal-title":"Value Health."},{"issue":"8","key":"827_CR24","first-page":"817","volume":"35","author":"C Hollman","year":"2017","unstructured":"Hollman C, Paulden M, Pechlivanoglou P, McCabe CJP. A comparison of four software programs for implementing decision analytic cost-effectiveness models. 2017;35(8):817\u201330.","journal-title":"A comparison of four software programs for implementing decision analytic cost-effectiveness models."},{"issue":"4","key":"827_CR25","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/0272989X16651869","volume":"37","author":"C Williams","year":"2017","unstructured":"Williams C, Lewsey JD, Briggs AH, Mackay DF. Cost-effectiveness analysis in R using a multi-state modeling survival analysis framework: a tutorial. Med Decis Making. 2017;37(4):340\u201352.","journal-title":"Med Decis Making."},{"issue":"3","key":"827_CR26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1177\/0272989X18754513","volume":"38","author":"EM Krijkamp","year":"2018","unstructured":"Krijkamp EM, Alarid-Escudero F, Enns EA, Jalal HJ, Hunink MM, Pechlivanoglou P. Microsimulation modeling for health decision sciences using R: a tutorial. Med Decis Making. 2018;38(3):400\u201322.","journal-title":"Med Decis Making."},{"issue":"5","key":"827_CR27","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/0272989X12454579","volume":"32","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7. Med Decis Making. 2012;32(5):733\u201343.","journal-title":"Med Decis Making"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00827-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-019-00827-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00827-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T23:18:24Z","timestamp":1596669504000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-019-00827-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,7]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["827"],"URL":"https:\/\/doi.org\/10.1007\/s40273-019-00827-z","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,7]]},"assertion":[{"value":"7 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Research described in this article was funded through the Innovation and Value Initiative (IVI), a non-profit multi-stakeholder research organization.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jeroen P. Jansen, Devin Incerti, and Mark Linthicum are employees of Precision Medicine Group. Devin Incerti and Jeroen P. Jansen are shareholders of Precision Medicine Group. IVI contracted Precision Medicine Group for research activities related to this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}